Literature DB >> 23391427

TREM2 is associated with the risk of Alzheimer's disease in Spanish population.

Bruno A Benitez1, Breanna Cooper, Pau Pastor, Sheng-Chih Jin, Elena Lorenzo, Sebastian Cervantes, Carlos Cruchaga.   

Abstract

Two recent studies have reported the association of rs75932628-T in the TREM2 gene with the risk for Alzheimer's disease (AD). Rs75932628-T is a rare nonsynonymous variant (p.R47H) that confers a high risk of AD with an effect size similar to that of the APOE ɛ4 allele. However, this association has not been replicated in any independent studies to date. The allelic frequency of rs75932628 varies according to the population from 0.02% to 0.63% among healthy controls. In an attempt to replicate the association between rs75932628-T and AD risk, we genotyped rs75932628 in a cohort of 504 AD subjects and 550 healthy controls from a Spanish population. Rs75932628-T showed a minor allele frequency of 0.3% among this cohort. Interestingly, in our study, rs75932628-T was found exclusively in 1.4% of AD cases (7/504), including 4 early-onset AD cases, and in none of the controls (n = 0/550). Here, we report the first positive replication study in a Spanish population and confirm that TREM2 rs75932628-T is associated with the risk for AD.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23391427      PMCID: PMC3596468          DOI: 10.1016/j.neurobiolaging.2012.12.018

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  13 in total

1.  An Italian family affected by Nasu-Hakola disease with a novel genetic mutation in the TREM2 gene.

Authors:  D Soragna; L Papi; M T Ratti; R Sestini; R Tupler; L Montalbetti
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-06       Impact factor: 10.154

2.  Nasu-Hakola disease with a splicing mutation of TREM2 in a Japanese family.

Authors:  Y Numasawa; C Yamaura; S Ishihara; S Shintani; M Yamazaki; H Tabunoki; J-I Satoh
Journal:  Eur J Neurol       Date:  2010-12-22       Impact factor: 6.089

3.  Variant of TREM2 associated with the risk of Alzheimer's disease.

Authors:  Thorlakur Jonsson; Hreinn Stefansson; Stacy Steinberg; Ingileif Jonsdottir; Palmi V Jonsson; Jon Snaedal; Sigurbjorn Bjornsson; Johanna Huttenlocher; Allan I Levey; James J Lah; Dan Rujescu; Harald Hampel; Ina Giegling; Ole A Andreassen; Knut Engedal; Ingun Ulstein; Srdjan Djurovic; Carla Ibrahim-Verbaas; Albert Hofman; M Arfan Ikram; Cornelia M van Duijn; Unnur Thorsteinsdottir; Augustine Kong; Kari Stefansson
Journal:  N Engl J Med       Date:  2012-11-14       Impact factor: 91.245

4.  Using exome sequencing to reveal mutations in TREM2 presenting as a frontotemporal dementia-like syndrome without bone involvement.

Authors:  Rita João Guerreiro; Ebba Lohmann; José Miguel Brás; Jesse Raphael Gibbs; Jonathan D Rohrer; Nicole Gurunlian; Burcu Dursun; Basar Bilgic; Hasmet Hanagasi; Hakan Gurvit; Murat Emre; Andrew Singleton; John Hardy
Journal:  JAMA Neurol       Date:  2013-01       Impact factor: 18.302

5.  Mutations in TREM2 lead to pure early-onset dementia without bone cysts.

Authors:  Eliane Chouery; Valérie Delague; Anne Bergougnoux; Salam Koussa; Jean-Louis Serre; André Mégarbané
Journal:  Hum Mutat       Date:  2008-09       Impact factor: 4.878

6.  Exome-sequencing confirms DNAJC5 mutations as cause of adult neuronal ceroid-lipofuscinosis.

Authors:  Bruno A Benitez; David Alvarado; Yefei Cai; Kevin Mayo; Sumitra Chakraverty; Joanne Norton; John C Morris; Mark S Sands; Alison Goate; Carlos Cruchaga
Journal:  PLoS One       Date:  2011-11-04       Impact factor: 3.240

7.  Rare variants in APP, PSEN1 and PSEN2 increase risk for AD in late-onset Alzheimer's disease families.

Authors:  Carlos Cruchaga; Gabe Haller; Sumitra Chakraverty; Kevin Mayo; Francesco L M Vallania; Robi D Mitra; Kelley Faber; Jennifer Williamson; Tom Bird; Ramon Diaz-Arrastia; Tatiana M Foroud; Bradley F Boeve; Neill R Graff-Radford; Pamela St Jean; Michael Lawson; Margaret G Ehm; Richard Mayeux; Alison M Goate
Journal:  PLoS One       Date:  2012-02-01       Impact factor: 3.240

8.  TREM2 variants in Alzheimer's disease.

Authors:  Rita Guerreiro; Aleksandra Wojtas; Jose Bras; Minerva Carrasquillo; Ekaterina Rogaeva; Elisa Majounie; Carlos Cruchaga; Celeste Sassi; John S K Kauwe; Steven Younkin; Lilinaz Hazrati; John Collinge; Jennifer Pocock; Tammaryn Lashley; Julie Williams; Jean-Charles Lambert; Philippe Amouyel; Alison Goate; Rosa Rademakers; Kevin Morgan; John Powell; Peter St George-Hyslop; Andrew Singleton; John Hardy
Journal:  N Engl J Med       Date:  2012-11-14       Impact factor: 91.245

9.  Pooled-DNA sequencing identifies novel causative variants in PSEN1, GRN and MAPT in a clinical early-onset and familial Alzheimer's disease Ibero-American cohort.

Authors:  Sheng Chih Jin; Pau Pastor; Breanna Cooper; Sebastian Cervantes; Bruno A Benitez; Cristina Razquin; Alison Goate; Carlos Cruchaga
Journal:  Alzheimers Res Ther       Date:  2012-08-20       Impact factor: 6.982

10.  DAP12/TREM2 deficiency results in impaired osteoclast differentiation and osteoporotic features.

Authors:  Juha Paloneva; Jami Mandelin; Anna Kiialainen; Tom Bohling; Johannes Prudlo; Panu Hakola; Matti Haltia; Yrjo T Konttinen; Leena Peltonen
Journal:  J Exp Med       Date:  2003-08-18       Impact factor: 14.307

View more
  72 in total

1.  Cerebrospinal fluid soluble TREM2 is higher in Alzheimer disease and associated with mutation status.

Authors:  Laura Piccio; Yuetiva Deming; Jorge L Del-Águila; Laura Ghezzi; David M Holtzman; Anne M Fagan; Chiara Fenoglio; Daniela Galimberti; Barbara Borroni; Carlos Cruchaga
Journal:  Acta Neuropathol       Date:  2016-01-11       Impact factor: 17.088

2.  The PSEN1, p.E318G variant increases the risk of Alzheimer's disease in APOE-ε4 carriers.

Authors:  Bruno A Benitez; Celeste M Karch; Yefei Cai; Sheng Chih Jin; Breanna Cooper; David Carrell; Sarah Bertelsen; Lori Chibnik; Julie A Schneider; David A Bennett; Anne M Fagan; David Holtzman; John C Morris; Alison M Goate; Carlos Cruchaga
Journal:  PLoS Genet       Date:  2013-08-22       Impact factor: 5.917

Review 3.  TREM2 variants: new keys to decipher Alzheimer disease pathogenesis.

Authors:  Marco Colonna; Yaming Wang
Journal:  Nat Rev Neurosci       Date:  2016-02-25       Impact factor: 34.870

Review 4.  Triggering receptor expressed on myeloid cells 2 (TREM2): a potential therapeutic target for Alzheimer disease?

Authors:  Yuetiva Deming; Zeran Li; Bruno A Benitez; Carlos Cruchaga
Journal:  Expert Opin Ther Targets       Date:  2018-06-20       Impact factor: 6.902

5.  Genome-wide association study identifies four novel loci associated with Alzheimer's endophenotypes and disease modifiers.

Authors:  Yuetiva Deming; Zeran Li; Manav Kapoor; Oscar Harari; Jorge L Del-Aguila; Kathleen Black; David Carrell; Yefei Cai; Maria Victoria Fernandez; John Budde; Shengmei Ma; Benjamin Saef; Bill Howells; Kuan-Lin Huang; Sarah Bertelsen; Anne M Fagan; David M Holtzman; John C Morris; Sungeun Kim; Andrew J Saykin; Philip L De Jager; Marilyn Albert; Abhay Moghekar; Richard O'Brien; Matthias Riemenschneider; Ronald C Petersen; Kaj Blennow; Henrik Zetterberg; Lennart Minthon; Vivianna M Van Deerlin; Virginia Man-Yee Lee; Leslie M Shaw; John Q Trojanowski; Gerard Schellenberg; Jonathan L Haines; Richard Mayeux; Margaret A Pericak-Vance; Lindsay A Farrer; Elaine R Peskind; Ge Li; Antonio F Di Narzo; John S K Kauwe; Alison M Goate; Carlos Cruchaga
Journal:  Acta Neuropathol       Date:  2017-02-28       Impact factor: 17.088

6.  TREM2 variants and risk of Alzheimer's disease: a meta-analysis.

Authors:  Yanjun Lu; Wei Liu; Xiong Wang
Journal:  Neurol Sci       Date:  2015-06-03       Impact factor: 3.307

7.  Frontobasal gray matter loss is associated with the TREM2 p.R47H variant.

Authors:  Elkin O Luis; Sara Ortega-Cubero; Isabel Lamet; Cristina Razquin; Carlos Cruchaga; Bruno A Benitez; Elena Lorenzo; Jaione Irigoyen; Maria A Pastor; Pau Pastor
Journal:  Neurobiol Aging       Date:  2014-06-17       Impact factor: 4.673

8.  Preparation, crystallization, and preliminary crystallographic analysis of wild-type and mutant human TREM-2 ectodomains linked to neurodegenerative and inflammatory diseases.

Authors:  Daniel L Kober; Kelsey M Wanhainen; Britney M Johnson; David T Randolph; Michael J Holtzman; Tom J Brett
Journal:  Protein Expr Purif       Date:  2014-02-07       Impact factor: 1.650

Review 9.  Estrogens, Neuroinflammation, and Neurodegeneration.

Authors:  Alessandro Villa; Elisabetta Vegeto; Angelo Poletti; Adriana Maggi
Journal:  Endocr Rev       Date:  2016-05-19       Impact factor: 19.871

10.  The triggering receptor expressed on myeloid cells 2 (TREM2) is associated with enhanced inflammation, neuropathological lesions and increased risk for Alzheimer's dementia.

Authors:  Panos Roussos; Pavel Katsel; Peter Fam; Weilun Tan; Dushyant P Purohit; Vahram Haroutunian
Journal:  Alzheimers Dement       Date:  2014-12-09       Impact factor: 21.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.